Quest Diagnostics Incorporated (DGX)
NYSE: DGX · Real-Time Price · USD
255.60
+8.54 (3.46%)
At close: Nov 4, 2026, 4:00 PM EST
256.50
+0.90 (0.35%)
After-hours: Nov 4, 2026, 7:01 PM EST
Quest Diagnostics Stock Forecast
Stock Price Forecast
According to 17 analysts polled by S&P Global, Quest Diagnostics stock has a consensus rating of "Buy" and an average price target of $257.27. The average 1-year stock price forecast is 0.65% higher than the current stock price, while the lowest is $235 (-8.06%) and the highest is $279 (+9.15%).
Price Target: $257.27 (+0.65%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Quest Diagnostics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 9 | 8 | 7 | 7 | 7 | 8 |
| Sell | 0 | 1 | 1 | 1 | 1 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 18 | 18 | 17 | 17 | 17 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| J.P. Morgan | J.P. Morgan | Hold Maintains $260 | Hold | Maintains | $260 | +1.72% | Oct 30, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Reiterates $260 | Buy | Reiterates | $260 | +1.72% | Oct 23, 2026 |
| Robert W. Baird | Robert W. Baird | Hold Maintains $260 → $262 | Hold | Maintains | $260 → $262 | +2.50% | Oct 23, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Maintains $265 | Buy | Maintains | $265 | +3.68% | Oct 23, 2026 |
| Barclays | Barclays | Buy Maintains $260 | Buy | Maintains | $260 | +1.72% | Oct 23, 2026 |
Financial Forecast
Revenue This Year
12.08B
from 11.04B
Increased by 9.51%
Revenue Next Year
12.62B
from 12.08B
Increased by 4.45%
EPS This Year
11.32
from 9.85
Increased by 14.90%
EPS Next Year
11.98
from 11.32
Increased by 5.83%
EPS and Forward PE are based on non-GAAP adjusted numbers.